Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TelyRx HoldingsTELYF +1.62%12 Net Cash per Share is $0.06 as of Jun. 2026. GuruFocus rates TELYF with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 135 Healthcare Providers & Services companies, TelyRx Holdings ranks worse than 82.96% on this metric.
The historical rank and industry rank for TelyRx Holdings's Net Cash per Share or its related term are showing as below:
TELYF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 26.33 Med: 26.33 Max: 27.77
Current: 26.86
During the past 3 years, the highest Price-to-Net-Cash Ratio of TelyRx Holdings was 27.77. The lowest was 26.33. And the median was 26.33.
TELYF's Price-to-Net-Cash is ranked worse than 82.96% of 135
companies
in the Healthcare Providers & Services industry
Industry Median: 8.81
vs TELYF: 26.86
TelyRx Holdings (OTCPK:TELYF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
TelyRx Holdings Net Cash per Share Related Terms
TelyRx Holdings Net Cash per Share Historical Data
* Premium members only.
The historical data trend for TelyRx Holdings's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, TelyRx Holdings's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TelyRx Holdings Price-to-Net-Cash vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TelyRx Holdings's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where TelyRx Holdings's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
TelyRx Holdings's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TelyRx Holdings (TELYF) has a Net Cash per Share of $0.06 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on TelyRx Holdings and its competitors. According to the industry distribution chart, TelyRx Holdings ranks #112 out of 135 companies in the Healthcare Providers & Services industry, placing it in the top 83%.
Is TelyRx Holdings' Net Cash per Share too high?
TelyRx Holdings' current Net Cash per Share is $0.06. The Healthcare Providers & Services industry median Net Cash per Share is 8.81. TelyRx Holdings' value of $0.06 is 99.3% below this industry median. Based on the distribution chart, TelyRx Holdings ranks #112 out of 135 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, TelyRx Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does TelyRx Holdings' Net Cash per Share compare to ?
According to the Healthcare Providers & Services industry distribution chart, TelyRx Holdings ranks #112 out of 135 companies for Net Cash per Share. This places TelyRx Holdings in the lower half of its industry. The industry median Net Cash per Share is 8.81. TelyRx Holdings' value of $0.06 is 99.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Healthcare Providers & Services company?
The median Net Cash per Share among Healthcare Providers & Services companies is 8.81, based on 135 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TelyRx Holdings's current Net Cash per Share of $0.06 is 99.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on TelyRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median Net Cash per Share is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TelyRx Holdings's current Net Cash per Share is $0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TelyRx Holdings stock overvalued right now?
TelyRx Holdings (TELYF) has a current Net Cash per Share of $0.06. The current Net Cash per Share is $0.06 and 99.3% below the Healthcare Providers & Services industry median of 8.81. TelyRx Holdings' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For TelyRx Holdings (TELYF), the current Net Cash per Share is $0.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TelyRx Holdings Inc is a vertically integrated technology enabled healthcare and pharmacy services provider, operating a digital pharmacy platform that connects patients with independent, state-licensed providers. The TelyRx platform provides the Providers with access to a clinically focused electronic medical records system and the ability for them to electronically prescribe. TelyRx enables patient access to a risk-curated formulary of over 450 noncontrolled, and non-compounded prescription medications selected by the Providers to address a broad cross-section of everyday chronic and acute ailments.
12GF Score
Get the complete analysis for TELYF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELYF has been successfully added to your 
